Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation
- PMID: 24793947
- DOI: 10.1016/j.vaccine.2014.04.043
Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation
Abstract
Nanotechnology promises a revolution in medicine including through new vaccine approaches. The use of nanoparticles in vaccination has, to date, focused on attaching antigen directly to or within nanoparticle structures to enhance antigen uptake by immune cells. Here we question whether antigen incorporation with the nanoparticle is actually necessary to boost vaccine effectiveness. We show that the immunogenicity of a sub-unit protein antigen was significantly boosted by formulation with silica nanoparticles even without specific conjugation of antigen to the nanoparticle. We further show that this effect was observed only for virus-sized nanoparticles (50 nm) but not for larger (1,000 nm) particles, demonstrating a pronounced effect of nanoparticle size. This non-attachment approach has potential to radically simplify the development and application of nanoparticle-based formulations, leading to safer and simpler nanoparticle applications in vaccine development.
Keywords: Adjuvant; Capsomere; Nanoparticle; Silica; Vaccine; Virus-like particle.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.PLoS One. 2015 Mar 10;10(3):e0117203. doi: 10.1371/journal.pone.0117203. eCollection 2015. PLoS One. 2015. PMID: 25756283 Free PMC article.
-
A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.Vaccine. 2014 May 30;32(26):3216-22. doi: 10.1016/j.vaccine.2014.04.011. Epub 2014 Apr 13. Vaccine. 2014. PMID: 24731807
-
Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.Vaccine. 2014 Jun 17;32(29):3651-5. doi: 10.1016/j.vaccine.2014.04.062. Epub 2014 May 2. Vaccine. 2014. PMID: 24795225
-
An overview on the role of silica-based materials in vaccine development.Expert Rev Vaccines. 2016 Nov;15(11):1449-1462. doi: 10.1080/14760584.2016.1188009. Epub 2016 May 31. Expert Rev Vaccines. 2016. PMID: 27160927 Review.
-
Nanoparticle vaccines.Vaccine. 2014 Jan 9;32(3):327-37. doi: 10.1016/j.vaccine.2013.11.069. Epub 2013 Dec 2. Vaccine. 2014. PMID: 24295808 Review.
Cited by
-
Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.Mol Pharm. 2021 Feb 1;18(2):576-592. doi: 10.1021/acs.molpharmaceut.0c00383. Epub 2020 Aug 17. Mol Pharm. 2021. PMID: 32787280 Free PMC article. Review.
-
Applications and perspectives of nanomaterials in novel vaccine development.Medchemcomm. 2017 Oct 17;9(2):226-238. doi: 10.1039/c7md00158d. eCollection 2018 Feb 1. Medchemcomm. 2017. PMID: 30108916 Free PMC article. Review.
-
Amorphous silicon dioxide nanoparticles modulate immune responses in a model of allergic contact dermatitis.Sci Rep. 2019 Mar 25;9(1):5085. doi: 10.1038/s41598-019-41493-7. Sci Rep. 2019. PMID: 30911099 Free PMC article.
-
Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.PLoS One. 2014 Dec 1;9(12):e114006. doi: 10.1371/journal.pone.0114006. eCollection 2014. PLoS One. 2014. PMID: 25436773 Free PMC article.
-
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.PLoS One. 2015 Mar 10;10(3):e0117203. doi: 10.1371/journal.pone.0117203. eCollection 2015. PLoS One. 2015. PMID: 25756283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
